Efficacy, Tolerability, and Safety of Lanthanum Carbonate in Hyperphosphatemia: A 6-Month, Randomized, Comparative Trial versus Calcium Carbonate

S. Karger AG - Tập 100 Số 1 - Trang c8-c19
Alastair J. Hutchison1, Bart Maes2, Johan Vanwalleghem3, G. Asmus4, Essam Hassan Eldrehmy5, R. E. Schmieder6, Wolfgang Backs7, R. Jamar8, Andre Vosskühler9
1Manchester Institute of Nephrology and Transplantation, The Royal Infirmary, Manchester, UK
2Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
3Virga Jesse Ziekenhuis, Hasselt, Belgium
4KfH-Dialysezentrum, Berlin, Germany
5Freeman Hospital, Newcastle upon Tyne, UK
6Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
7Dialysezentrum Barmbek, Hamburg, Germany
8Imelda Ziekenhuis, Bonheiden, Belgium
9KfH-Dialysezentrum, Bottrop, Germany

Tóm tắt

<i>Background/Aims:</i> Hyperphosphatemia is an important clinical consequence of renal failure, and its multiple adverse systemic effects are associated with significantly increased risks of morbidity and mortality in dialysis patients. Existing oral phosphate binders have not permitted control of serum phosphate within currently accepted guidelines. This study compares lanthanum carbonate with calcium carbonate for control of serum phosphate in hemodialysis patients. <i>Methods:</i> In this European multicentre study, 800 patients were randomised to receive either lanthanum or calcium carbonate and the dose titrated over 5 weeks to achieve control of serum phosphate. Serum levels of phosphate, calcium and parathryoid hormone were followed over the following 20 weeks. <i>Results:</i> Around 65% of patients in each group achieved phosphate control, but in the calcium carbonate group this was at the expense of significant hypercalcemia (20.2% of patients vs. 0.4%). Consequently, calcium x phosphate product tended to be better controlled in the lanthanum group. <i>Conclusion:</i> This 6-month study demonstrates that serum phosphate control with lanthanum carbonate (750–3,000 mg/day) is similar to that seen with calcium carbonate (1,500–9,000 mg/day), but with a significantly reduced incidence of hypercalcemia. Lanthanum carbonate is well tolerated and may be more effective in reducing calcium x phosphate product than calcium carbonate.

Từ khóa


Tài liệu tham khảo

10.1053%2Fajkd.1998.v31.pm9531176

10.1016%2FS0140-6736%2801%2906299-7

10.1093%2Fndt%2F15.suppl_5.32

10.1515%2FCCLM.2000.032

10.2165%2F00023210-200115090-00003

10.1053%2Fajkd.2001.29283

10.1016%2FS0272-6386%2897%2990352-8

10.1038%2Fki.1993.64

10.1046%2Fj.1523-1755.2002.00434.x

10.1046%2Fj.1523-1755.1999.00240.x

10.1093%2Fndt%2F13.9.2303

10.1053%2Fjarr.2002.34843

10.1093%2Fndt%2Fgfh282

10.1016%2FS0272-6386%2803%2900554-7

10.1056%2FNEJM200005183422003

Thông tin
Thông tin xuất bản

S. Karger AG

Tập 100 Số 1

c8-c19

Thông tin tác giả